ES2614813T3 - Nuevos tratamientos terapéuticos usando centaquina - Google Patents

Nuevos tratamientos terapéuticos usando centaquina Download PDF

Info

Publication number
ES2614813T3
ES2614813T3 ES10770318.3T ES10770318T ES2614813T3 ES 2614813 T3 ES2614813 T3 ES 2614813T3 ES 10770318 T ES10770318 T ES 10770318T ES 2614813 T3 ES2614813 T3 ES 2614813T3
Authority
ES
Spain
Prior art keywords
centaquine
hemorrhagic shock
lactate
shock
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10770318.3T
Other languages
English (en)
Spanish (es)
Inventor
Anil Gulati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Midwestern University Downers Grove
Midwestern University Glendale
Original Assignee
Midwestern University Downers Grove
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Midwestern University Downers Grove, Midwestern University Glendale filed Critical Midwestern University Downers Grove
Application granted granted Critical
Publication of ES2614813T3 publication Critical patent/ES2614813T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
ES10770318.3T 2009-04-30 2010-04-29 Nuevos tratamientos terapéuticos usando centaquina Active ES2614813T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17425709P 2009-04-30 2009-04-30
US174257P 2009-04-30
PCT/US2010/032942 WO2010127096A2 (en) 2009-04-30 2010-04-29 Novel therapeutic treatments using centhaquin

Publications (1)

Publication Number Publication Date
ES2614813T3 true ES2614813T3 (es) 2017-06-02

Family

ID=43032771

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10770318.3T Active ES2614813T3 (es) 2009-04-30 2010-04-29 Nuevos tratamientos terapéuticos usando centaquina

Country Status (10)

Country Link
US (2) US20120083447A1 (https=)
EP (1) EP2424529B1 (https=)
JP (2) JP5498571B2 (https=)
CN (2) CN103989682B (https=)
AU (1) AU2010241564B2 (https=)
BR (1) BRPI1013903B1 (https=)
CA (1) CA2759791C (https=)
ES (1) ES2614813T3 (https=)
PL (1) PL2424529T3 (https=)
WO (1) WO2010127096A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
CN110354267A (zh) * 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
WO2016061583A1 (en) * 2014-10-17 2016-04-21 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
BR112020022395A2 (pt) * 2018-05-03 2021-04-13 Midwestern University Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina
WO2022240964A1 (en) * 2021-05-11 2022-11-17 Pharmazz, Inc. Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19)

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) * 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ １―ｍ―トリル―４―（Ｂ―２―キノリエチル）―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) * 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
CA1217141A (en) 1983-04-26 1987-01-27 Frank J. Macri Norepinephrine potentiated compositions and method of use
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
WO2002049630A2 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
WO2003009805A2 (en) 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
CA2502848C (en) 2002-10-24 2012-10-02 The Board Of Trustees Of The University Of Illinois Use of irl-1620 and paclitaxel for preventing and treating breast tumors
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
JP2009506119A (ja) 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
AU2007230887A1 (en) 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
PL2182977T4 (pl) 2007-08-21 2017-01-31 Midwestern University Kompozycje do leczenia udaru lub incydentów mózgowo-naczyniowych za pomocą agonisty receptora endoteliny B
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
US8518969B2 (en) 2010-06-17 2013-08-27 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
CN110354267A (zh) 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
WO2015006324A2 (en) 2013-07-08 2015-01-15 Midwesterern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
BR112020022395A2 (pt) 2018-05-03 2021-04-13 Midwestern University Alterações em receptores de endotelina em seguida a hemorragia e ressuscitação por centaquina

Also Published As

Publication number Publication date
JP5498571B2 (ja) 2014-05-21
JP5727642B2 (ja) 2015-06-03
BRPI1013903B1 (pt) 2020-03-03
JP2014141502A (ja) 2014-08-07
US20180085461A1 (en) 2018-03-29
CA2759791C (en) 2018-04-10
CN102458399A (zh) 2012-05-16
WO2010127096A2 (en) 2010-11-04
CN103989682A (zh) 2014-08-20
CN102458399B (zh) 2014-04-23
AU2010241564A1 (en) 2011-11-17
EP2424529A2 (en) 2012-03-07
AU2010241564A2 (en) 2012-10-04
PL2424529T3 (pl) 2017-06-30
CN103989682B (zh) 2016-03-30
EP2424529A4 (en) 2012-11-28
AU2010241564B2 (en) 2014-07-31
JP2012525422A (ja) 2012-10-22
WO2010127096A3 (en) 2011-03-24
BRPI1013903A2 (pt) 2016-07-19
EP2424529B1 (en) 2016-12-28
US20120083447A1 (en) 2012-04-05
US10828368B2 (en) 2020-11-10
CA2759791A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
Mallet et al. Cardioprotection by intermittent hypoxia conditioning: evidence, mechanisms, and therapeutic potential
Adigun Comparison of intravenous ephedrine with phenylephrine for the maintenance of arterial blood pressure during elective caesarean section under spinal anaesthesia
Uilenreef et al. Dexmedetomidine continuous rate infusion during isoflurane anaesthesia in canine surgical patients
Mentes et al. Effect of intraoperative magnesium sulphate infusion on pain relief after laparoscopic cholecystectomy
Brücken et al. Dose dependent neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by KATP—channel opening
ES2614813T3 (es) Nuevos tratamientos terapéuticos usando centaquina
ES2278441T3 (es) Uso de la dexmedetomidina para sedacion en uci.
Silfvast et al. Comparison of Adrenaline and Phenylephrine in Out‐of‐Hospital Cardiopulmonary Resuscitation: A Double‐Blind Study
Fyneface-Ogan et al. Comparative effects of single shot intrathecal bupivacaine with dexmedetomidine and bupivacaine with fentanyl on labor outcome
US20180028594A1 (en) Peripheral kappa opioid receptor agonists for hard tissue pain
Bharathwaj et al. Comparison of dexmedetomidine versus propofol-based anaesthesia for controlled hypotension in functional endoscopic sinus surgery
Ship et al. Radiotherapy-induced salivary dysfunction
Weaver Hyperbaric medicine for the hospital-based physician
Conde Ruiz et al. Successful cardiopulmonary resuscitation in a sevoflurane anaesthetized horse that suffered cardiac arrest at recovery
Nakagawa et al. Treatment of refractory intracranial hypertension with 23.4% saline in children with severe traumatic brain injury
Jang et al. Cardiovascular effect of epinephrine in endodontic microsurgery: a review
Fahr The treatment of cardiac irregularities
Chatterjee et al. Resuscitation in massive obstetric haemorrhage using an intraosseous needle
Uscategui et al. Pre-emptive methadone or tramadol analgesia for mastectomy and ovariohysterectomy in bitches
Annecke et al. Propofol-related infusion syndrome induced by “moderate dosage” in a patient with severe head trauma
Chia et al. Cardiopulmonary Arrest Following a Single 25 Mg Dose of Quetiapine: A Case Report
Nour Eldeen et al. Magnesium Sulphate, Lidocaine or Nitroglycerin for Controlled Hypotension and Quality of the Surgical Field in Patients Undergoing Tympanoplasty
Smith Management of chronic degenerative mitral valve disease in dogs
Mostafa et al. Impact of modified del Nido versus traditional cold cardioplegia on myocardial protection in cardiac patients with a low ejection fraction
Hughes et al. A hiccup in hiccup management: Cardiac arrest from previously undiagnosed congenital long QT syndrome